Bio-Bridge Science Receives Approval for Acquisition of Xinheng Baide

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged 
      in the commercial development of vaccines for the prevention and 
      treatment of human infectious diseases announced today that it had 
      received a certificate of approval from the Department of Commerce of 
      Inner Mongolia Autonomous Region of the PRC for approving the 
      acquisition of Xinheng Baide Biotechnology Co. Ltd. BGES has one month 
      to close the transaction, and obtain the new business license. The 
      transaction is expected to close before the end of July.
    
    
      Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, “We 
      are happy to see the Inner Mongolia government has approved our 
      acquisition of Xinheng Baide. The completion of the acquisition of 
      Xinheng Baide will be a significant first step of our acquisition 
      strategy. We believe Xinheng Baide will provide revenues and 
      complementary products to Bio-Bridge.”
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.